Rebuilding lives and offering hope to people with neurodegenerative diseases (ESL)
Avrion Therapeutics is developing a treatment for amyotrophic lateral sclerosis (ALS), an incurable neurodegenerative disease that leads to death within 3 to 5 years.
- Brand positioning
- Visual identity
In the highly-specialized environment of biotech startups targeting DNA, this EPFL spin-off stands out from the pack for its precision and technological simplicity. Our branding work was driven by a desire to veer from the well-trodden path and shy away from the symbolism used by competitors. All while applying a minimalist visual approach.
We chose to focus on the human being and their life stories rather than focusing directly on technology. Behind each person with the disease is DNA: a life searching for a glimmer of hope that one day they will be able to live a normal life again.